چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Aims: STAT3 signaling is critical for Th17 development that plays an important role in multiple sclerosis path-ogenesis. To evaluate the anti-inflammatory and regulatory T cells effects of JAK1/2 and STAT3 inhibition, we assessed the JAK 1/2 inhibitor ruxolitinib effects on Th17 cell/Tregs balance. Main methods: Ruxolitinib was administered to experimental autoimmune encephalomyelitis (EAE) mice via oral gavage, and its effects were assessed. The expression of pro-inflammatory and anti-inflammatory cytokines, including IL-17A and IL-10, were analyzed by real-time PCR. The frequency of Th17 cells and Tregs were evaluated by flow cytometry. Key finding: Ruxolitinib ameliorated the EAE severity and decreased the proportion of Th17 cells and inflam-matory markers levels. In contrast, the balance of Tregs and the level of anti-inflammatory cytokine were increased in ruxolitinib-treated mice. Furthermore, ruxolitinib markedly decreased the expression of Th17 related transcription factor, RORɣt, whereas FOXP3 expression associated with Treg differentiation was increased. Significance: Our results show that ruxolitinib may be a promising therapeutic strategy for multiple sclerosis. |
| نویسنده | نفر چندم مقاله |
|---|---|
| آرزو حسینی | اول |
| توحید غریبی | دوم |
| عباس ابراهیمی کلان | چهارم |
| فرهاد جدیدی نیارق | پنجم |
| زهره بابالو | ششم |
| داریوش شانه بندی | هفتم |
| الهام باغبانی | هشتم |
| بهزاد برادران | نهم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 528-Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS).pdf | 1400/04/26 | 1912186 | دانلود |
